To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years (Aladdin)
A Multicenter, Single-group, Phase III Study to Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years Who Completed the Primary Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis by Participating in the Phase III Study, BR-DTPP-CT-301, or by Receiving Routine Vaccination
Sponsor: Boryung Biopharma Co., Ltd.
Listed as NCT04618640, this PHASE3 trial focuses on Diphtheria and Pertussis and remains ongoing. Sponsored by Boryung Biopharma Co., Ltd., it has been updated 6 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boryung Biopharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .